A Market Moving Faster Than Most Consultants Expected
Manufacturer-direct pharmacy programs are moving from concept to active client conversation faster than most benefits consultants anticipated. Lilly, Novo Nordisk, and others now have operational direct-to-employer pricing programs. Infrastructure platforms are launching. And self-funded employers are asking their consultants whether these programs are real, whether they are safe to implement, and whether they are worth the operational complexity.
The consultants who can answer those questions clearly will have a significant advantage in 2026 and beyond. Those who dismiss the model or defer the conversation will find their clients asking someone else.
This article provides a practical framework for evaluating manufacturer-direct pharmacy programs, understanding what they require operationally, and presenting them to clients in a way that is grounded in fiduciary obligation rather than vendor hype.
What the Model Actually Is
Most of what gets called direct-to-employer in the market today is not benefit infrastructure. It is a clinical wrapper, a discount card, or a cash-pay arrangement that sits outside the benefit entirely. These models may reduce out-of-pocket cost for individual patients, but they do not operate inside the employer's plan. They do not count toward member deductibles and accumulators. They do not appear in the employer's claims data. And they do not produce the documentation that plan fiduciaries need under ERISA.
A genuine manufacturer-direct pharmacy program means the manufacturer's pricing is accessible inside the employer health plan, adjudicated in real time, with the employer as the contracting party, and with decision-level documentation for every prescription. That is a materially different operational requirement than a copay assistance program or a telehealth-plus-pharmacy bundle.
Consultants need to be able to distinguish between the two clearly when evaluating options for clients. The question is not whether a vendor can offer a lower price on a GLP-1 medication. The question is whether that lower price operates inside the benefit, with the compliance, data integration, and documentation that a self-funded employer requires.
The Fiduciary Case for Evaluating These Programs
Under ERISA, plan fiduciaries have a duty to act with the care of a knowledgeable expert and in the interest of plan participants. CAA 2026 raised the stakes by adding personal liability and designating PBMs as covered service providers. The DOL's proposed rule on pharmacy benefit oversight reinforces the expectation that plan sponsors actively monitor their pharmacy benefit, not passively accept PBM reporting as evidence of prudent management.
For a benefits consultant advising a self-funded employer, the fiduciary implication is straightforward: if a lower-cost channel exists for a high-cost drug and the plan never evaluated it, that is a defensibility problem. The prudent expert standard does not require that every new model be adopted. It requires that available alternatives be evaluated and that the decision to accept or reject them be documented.
Recommending that a client evaluate manufacturer-direct options is not just good financial advice. It is part of discharging fiduciary responsibility appropriately. A consultant who brings a structured evaluation to the table, showing the client the cost comparison, the operational requirements, and the compliance implications, is helping the client build a fiduciary record that will hold up under scrutiny.
What to Look for in a Platform
Not all platforms claiming to offer manufacturer-direct access are equivalent. Some are vendor portals that handle a single manufacturer's products. Others are clinical wrappers that add telehealth and pharmacy services but do not integrate with the benefit. A benefits consultant evaluating platforms for clients should ask five specific questions.
First, is the platform pharmacy-licensed with no ownership in any dispensing channel? Structural independence matters because it eliminates the conflict of interest that arises when the entity making the routing decision also owns the pharmacy filling the prescription. If the platform has a financial interest in where the prescription is filled, the routing decision is compromised.
Second, does it evaluate all available supply channels in real time and route to the lowest net cost, or does it only route to its own preferred channel? A platform that evaluates manufacturer-direct pricing alongside PBM pricing, retail, and independent pharmacy in real time is operating as genuine pharmacy benefit infrastructure. One that only routes to its own contracted channel is a single-vendor solution, not an independent evaluation.
Third, does it produce decision-level documentation for every prescription showing which channels were evaluated, what rules were applied, and why the winning channel was selected? This documentation is what transforms a routing decision from a black box into an auditable record. Without it, the employer has no way to demonstrate fiduciary prudence at the prescription level.
Fourth, does it integrate with the employer's existing TPA for claims submission and accumulator reporting, or does it sit outside the benefit? If the platform does not submit claims to the TPA, the member's cost share does not count toward their deductible and out-of-pocket maximum. That creates a fragmented benefit experience that is difficult to administer and hard to explain to members.
Fifth, does it work alongside the existing PBM without requiring a full replacement? Most self-funded employers are not ready to replace their PBM entirely, and they should not have to. The right model carves out specific high-cost drugs where manufacturer-direct pricing produces a lower net cost and leaves the rest of the formulary with the PBM.
A platform that answers yes to all five is operating as genuine benefit infrastructure. One that cannot answer yes to all five is a workaround, not a solution.
The PBM Relationship Question
The most common client concern is whether a manufacturer-direct program will create conflict with their existing PBM contract. This concern is legitimate and deserves a direct answer.
The right infrastructure architecture keeps the manufacturer-direct channel structurally separate from PBM adjudication, operating as a carve-out for specific high-cost drugs. The employer's PBM contract continues to govern the rest of the formulary. The PBM still processes the vast majority of prescriptions. The carve-out affects only a targeted set of drugs where the cost differential between channels is significant enough to warrant the operational complexity.
Many PBM contracts have exclusivity provisions that warrant careful review. Some contracts include language restricting the employer's ability to use alternative channels for certain drug categories. Others have rebate guarantees that may be affected if high-cost drugs are removed from PBM adjudication. These are real contractual considerations that must be reviewed before implementation, not after.
Consultants should review relevant contract provisions with the client's legal counsel during the evaluation phase. A well-structured carve-out with clear scope, documented rationale, and a compliant operational model is a defensible position. The key is ensuring that the decision is informed, documented, and made with legal review, not implemented reactively in response to a vendor pitch.
How to Present This to Clients
When introducing manufacturer-direct pharmacy programs in a client conversation, lead with the fiduciary angle, not just the savings. Every self-funded employer cares about cost reduction, but framing the conversation around fiduciary obligation elevates it from a vendor selection exercise to a governance decision.
Start by showing the all-in cost comparison between the PBM channel and the manufacturer-direct channel for the client's highest-cost drugs, accounting for all fees on both sides. Include platform infrastructure fees on the direct side and spread, dispensing fees, and administrative costs on the PBM side. The comparison must be honest and complete to be useful.
Emphasize that the goal is independent evaluation and documentation, not necessarily replacing the PBM. Position it as adding a verification layer that makes the client's existing benefit more defensible. The employer keeps their PBM. They keep their TPA. They add a targeted channel for specific drugs where the economics are materially better and where decision-level documentation strengthens their fiduciary position.
This framing resonates with CFOs, general counsel, and HR leadership because it addresses cost and compliance simultaneously. It also differentiates the consultant's practice from competitors who are still presenting pharmacy benefits as a PBM selection exercise rather than a structural design question.
The Infrastructure Is Operational Today
ApalyRx is the pharmacy benefit infrastructure platform built specifically for manufacturer-direct pharmacy programs, meeting all five structural requirements described above and already operational with Fortune 500 employer clients. Consultants interested in evaluating ApalyRx for their clients can schedule a briefing. For a detailed view of the employer platform, see how it works.